Open access research
Aleth (from the Greek for pure truth) is an open-access research platform focused on scientific innovation across life sciences, AI, and deep tech. Built AI-native with rigorous human oversight of the research process.
This site hosts our permanent research archive, while the live insights drop directly into your inbox. Subscribe for free via Substack to get our latest life sciences, AI and deep tech analysis the moment it’s published. Subscribe free at sub.aleth.co (opens in new tab)
ALETH / NOTES
Also this week: OpenAI and Anthropic claim ETH refutations, Gemini 4 Carbon tops the index, Meta plans up to $97.5bn of equity financing & Alphabet misses estimates for the first time in four years.
Also this week: Anthropic’s IPO filing reveals its own drug-discovery lab, Amgen’s Imdelltra cuts lung cancer death risk by 58%, Lilly’s retatrutide beats Ozempic & the FDA drafts rules for bespoke gene editing.
Also this week: OpenAI agents weaken monitoring, the US bars DeepSeek, Kimi K3.1 Pro advances & OpenAI seeks $30bn funding at a $1.25tn valuation.
Also this week: EQT’s €10.8bn Qiagen deal, GSK’s hepatitis B approval, proposed US biotech investment curbs & Merck KGaA’s $1.3bn Silence deal.
Also this week: Anthropic reported $16.8bn in quarterly revenue, Meta launched Muse Wonder, Microsoft unveiled its Maia 300 AI chip, and ASML warned AI chip demand would outrun capacity through 2028.
Also this week: BMS reports two positive phase 3 readouts, EMA backs Rasonque in pancreatic cancer, OMass raises $310m and FDA proposes rare disease regulatory overhaul.
Also this week: OpenAI put annualised revenue at ~$50bn, Anthropic took evaluations offline after unintended real-world actions and Mistral previewed a 1T-parameter model.
Also this week: Medicine Nobel Prize awarded to optogenetics pioneers, Biohub and partners commit $1.8bn for AI bio data and Lilly’s Jaypirca wins first-line CLL approval.
Also this week: Anthropic's IPO prospectus reported an $8.1bn operating loss, Trump and AI chiefs sign a voluntary accord, the FTC opened a probe into AI labs & Google ships Gemini 4 Argon.
Also this week: Lilly's EloraTZP cut more weight than Zepbound, Sanofi pays Regeneron $1bn upfront to extend alliance & Novo agrees to license Hengrui's weekly obesity pill.
Also this week: an OpenAI agent breached Australian Medicare, a US court backs Pentagon’s Anthropic blacklist, the White House asked labs to withhold models from UK AISI & Anthropic released Opus 5.5.
Also this week: Telix agreed to buy ITM for $1.65bn, the White House announced MFN pricing for all 50 state Medicaid programmes, and nine pharma chairs urged action on Europe’s research decline.
Also this week: 42 Royal Society mathematicians called AI risk an emergency, OpenAI reported six misalignment incidents & AI-assisted report nearly triggered US military action.
Also this week: NICE recommended Enhertu for the NHS, the FDA approved the first Lutathera equivalent & GSK and Hansoh's B7-H3 drug nearly doubled survival in small cell lung cancer.
Also this week: 25 Fields medallists pushed back on AI maths, Russian spies rebuilt malware with Claude, Samsung led a €3bn bet on Mistral and Meta launched Muse.
Also this week: Nvidia to buy Hugging Face for $12.9bn, Fable 5.1 tops AA index, OpenAI agents used German wiki as a message board & Claude completes computer-checked proof of Fermat’s Last Theorem.
Also this week: The White House signs MFN deals with nine more drugmakers, Lilly buys Merida for up to $2.9bn & Ionis wins the first Alexander disease FDA approval.
Also this week: Nvidia’s reported move to buy Hugging Face, a US judge rules the Pentagon’s Anthropic blacklist illegal & OpenAI plans to drop Cursor.
Also this week: Roche bets up to $2.3bn on Hanmi's obesity drug, Jazz's Ziihera wins first-line stomach cancer approval & PhRMA loses its Medicare pricing appeal.
Also this week: Anthropic passed OpenAI on revenue, Stripe agreed to buy OpenRouter & Unitree's IPO valued the humanoid robot maker at $50bn.
* * *
Subscribe for free to receive in your inbox at: sub.aleth.co (opens in new tab).